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Introduction
Today vaccination is an uncontested way of fighting disease. It 
has enabled the control of several diseases, including diphtheria, 
tetanus, poliomyelitis and mumps (at least in certain parts of the 
world). However, new viruses are appearing, with the character-
istic of being able to mutate their genetic composition quickly 
(AIDS, SARS, Avian Flu H5N1, Swine Flu H1N1, and so on and 
so forth). In addition, the cost of developing vaccines precludes 
the targeting of all diseases. New vaccination strategies are there-
fore necessary in order to enable a response that is prompt and 
more appropriate than the current methods. DNA vaccination 
would seem to be one of the particularly promising methods at 
this time.
In the Eighties, Dubensky et al. reported for the first time that 
an in vivo DNA injection enabled a production of insulin.1 Then, 
in the Nineties the injection of purified plasmid DNA into mus-
cles of mice enabled detectable markers such as β-galactosidase.2 
The use of such methods was quickly envisaged for the purpose 
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of accelerating the development of new vaccines. However, this 
method then lost its interest because of its low effectiveness in 
tests on large primates even though it had proved to be very effec-
tive in treating smaller animals.3 In the course of the last ten 
years, great attention has been paid to the DNA delivery meth-
ods. It is indeed this stage that seemed to be limiting. Several 
avenues have been explored and have enabled new DNA deliv-
ery methods to be developed, one of which was electroporation, 
which seems currently to be the best injection method avail-
able.4,5 In vivo electrotransfer involves plasmid injection and 
application of high voltage pulses that, on one hand, transitorily 
disturb membranes and thus increase cells permeability and, on 
the other hand, promote electrophoresis of negatively charged 
DNA.6 This new injection method has rekindled interest in 
DNA vaccination, especially considering its multiple advantages 
compared with the production of protein antigens: stability of 
the DNA (easier transport and storage), identical production 
process for all vaccines (DNA production), no problems relat-
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reference CPMP/BWP/3088/99, 2001 and EMEA/CHMP/
GTWP/65260/2008, 2008). These recommendations are 
understandable not only because of the risks of allergic reactions 
that antibiotics resistances represent, but also because of the risk 
of selection of antibiotics resistant pathogenic bacteria. In the 
case of DNA vaccine, the refusal of antibiotic resistance gene use 
is completely relevant since this resistance gene forms an inte-
gral part of the product injected into the subject. We propose to 
replace this resistance to an antibiotic by the Staby® technology 
based on natural poison/antidote bacterial genes to insure the 
plasmid retention during cloning and DNA production.10-12
There is a large number of poison/antidote systems, including 
in bacteria used industrially for production of proteins used as 
medical products (antigen vaccines, etc).13-17 Among these sys-
tems, there is the ccd system composed of the ccdA (antidote) 
and ccdB genes (poison). The Staby® technology is based on the 
use of this ccd system. These bacterial genes are known since the 
Nineties.18,19 They are small in size (approximately 200 to 300 
bases each), naturally present in the genomes of the bacteria and 
on the plasmids, and they encode two small proteins.18,19 In a 
natural state, they are organized as an operon: a promoter fol-
lowed by the gene of the antidote (ccdA) and then by the gene of 
the poison (ccdB). The system regulating the expression (absence 
of RBS upstream of the poison ORF) ensures that the poison is 
produced only after the antidote.19 The protein antidote alone 
or in complex with the poison is able to repress the transcrip-
tion of both genes. The particular property of the ccd system 
is that it targets the DNA gyrase, a topoisomerase absent from 
the cells of higher eukaryotes. The poison is therefore not toxic 
for mammalian cells.20 The Staby® technology has already been 
applied to the production of recombinant proteins in Escherichia 
coli. This enables the plasmid encoding for the protein of interest 
to be stabilized in a bacterial population without the use of an 
antibiotic-resistance gene. Due to this particularly efficient sta-
bilization and to the saving of energy by avoiding the expression 
of resistance gene, the protein yield is increased significantly.10 
In order to obtain this stabilization, the ccdB gene is placed in 
the chromosome of the bacterium and the gene of the antidote is 
placed on the plasmid. Daughter cells not receiving the plasmid 
cannot survive (Fig. 1A). Moreover, in the presence of the anti-
dote, the expression of the poison is repressed, thereby preventing 
the selection of potential spontaneous mutant encoding inactive 
poison.
This technological base will enable us to build a new genera-
tion of DNA vaccines without antibiotic resistance gene. Indeed, 
the majority of DNA vaccines still encode a gene conferring resis-
tance to an antibiotic, despite the recommendations of regula-
tory agencies.21 In order to generate our new constructions, we 
modified the pStaby1.2 plasmid which contains the ccdA gene by 
replacing the prokaryotic promoter by the immediate early CMV 
promoter. The CMV promoter is followed by a thymidine kinase 
(TK) polyadenylate sequence and separated with the latter by a 
classical EcoRV cloning site (Fig. 1B). In the present study, we 
investigated three questions related to the use of Staby® technol-
ogy for the development and the production of DNA vaccines free 
of antibiotic resistance gene: (1) the potential toxicity of CcdA in 
development and production time when combating a pandemic, 
easy vaccine adaptation to a new serotype variant and “design” 
facility of multivalent vaccines (the presence of several genes is 
not a problem, unlike the presence of several different proteins 
with different biochemical characteristics).
Moreover, the use of plasmid DNA is regarded as safe in terms 
of integration and autoimmune reaction.7-9 Several clinical tri-
als for human vaccines are in progress (about a hundred in all) 
but none of them has yet been approved and marketed. On the 
other hand, to our knowledge, there are three DNA vaccines in 
existence that have been approved for animal use and several oth-
ers are in progress. The first on the market was a vaccine against 
Egyptian horse fever marketed in 2009 (West Nile virus, Fort 
Dodge Animal Health). The two others are vaccines for salmon 
(Aqua Health Ltd) and for dogs (vaccine against melanoma, 
Merial).
Presently, the resistant gene is used as a selection marker for 
the construction of the productive strain and the production 
of the plasmid DNA. However, it is recommended by regula-
tory agencies (FDA, USDA, EMA) for more than 15 years to 
avoid the use of antibiotics as selection marker (EMA document, 
Figure 1. (A) The staby® technology. The ccda protein encoded by the 
plasmid negatively regulates the transcription of the ccdB gene in the 
bacterial chromosome. In absence of plasmid, the bacterium died by 
producing the ccdB protein. (B) scheme of the pstabycMV-2 containing 
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use of ccdA is safe for eukaryotic cells when artificially overex-
pressed using the CMV promoter and a fortiori when using a 
prokaryotic promoter.
The second objective was to check the potential impact of 
Staby® selection system on the plasmid manufacturing process 
at an industrial scale. For this study, pStabyCMV-2-GOI was 
transformed into the E. coli CYS21 strain and used according 
to fedbatch fermentation processes. Fermentation yield obtained 
in this study was up to 1,350 mg plasmid/l (data not shown). 
This result shows that antibiotic free plasmid DNA containing 
the ccdA gene can be manufactured at large scale.
The third and last objective of the present study was to inves-
tigate the possibility to develop safe and efficacious DNA vac-
cines using Staby® technology. The induction of pseudo-rabies 
by SuHV-1 in mice was selected as an experimental model. With 
this goal in mind, a DNA candidate vaccine encoding glycopro-
tein D (gD) of SuHV-1 was produced. Its safety and efficacy 
was tested in mice as follow (Fig. 3). Mice were vaccinated by 
electrotransfer three times at three weeks interval, accompanied 
by three bleedings at day 7, 28 and 49 (the first electrotransfer 
being defined as day 0). This protocol did not induced detectable 
clinical signs, supporting the safety of the vaccination program.
The immune response induced by the vaccine was investi-
gated as follows. First, specific antibodies raised against SuHV-1 
gD were quantified by indirect immunofluorescent staining of 
MAC-T cells transiently expressing gD. The sera of the animals 
were used as first antibodies. Stained cells were analyzed by flow 
cytometry and the mean fluorescent intensity channel (MFI) 
was recorded as a relative measure of specific anti-gD antibody 
concentration in the serum of vaccinated animals (Fig. 4A). 
Specific antibodies were detected as early as 1 week after the first 
DNA immunization. Subsequent boosts drastically increased the 
concentration of antibodies. After the first boost we observed a 
3-fold increased in the MFI and a further 2-fold increase after 
the second boost (Fig. 4A). Second, neutralization assays were 
performed to investigate whether the antibodies produced were 
able to neutralize SuHV-1 infectivity. In the complement inde-
pendent neutralization assay used, the sera obtained after the first 
immunization did not neutralize SuHV-1. In contrast, sera col-
lected after the second and the third immunizations exhibited 
increasing concentrations of neutralizing antibodies for all mice 
of the group (Fig. 4B). Finally, as the results of the neutraliza-
tion assays suggested that the immune response conferred by 
pStabyCMV-2-gD vaccination could be protective, animals were 
exposed to a lethal challenge. Four weeks after the last immuni-
zation, mice were inoculated intramuscularly with the SuHV-1 
Phylaxia strain (Fig. 4C). Clinical examinations were performed 
for 15 days after viral inoculation. While none of the mice 
immunized with pStabyCMV-2-gD expressed pseudo-rabies 
clinical signs, all mice immunized with pStabyCMV-2 devel-
oped pseudo-rabies in a synchronized manner at the beginning 
of day 4 post-inoculation. These mice died or were euthanized 
for bioethic reasons during the same day. All together, the results 
present above demonstrate the potential of the Staby® technology 
for the development and the production of safe and efficacious 
DNA vaccines.
eukaryotic cells; (2) the industrial production of plasmid free of 
antibiotic resistance gene; and (3) the possibility to develop safe 
and efficacious DNA vaccine free of antibiotic resistance gene. 
To address the latter hypothesis, we developed a DNA candidate 
vaccine against Suid herpesvirus-1 (SuHV-1), the causative agent 
of Aujeszky’s disease in pigs.22 We took profit of the ability of this 
virus to cause a severe and lethal disease in mice (called pseudo-
rabies) to test the efficacy of the candidate vaccine developed. 
All together, the results of the present study demonstrated the 
potential of the Staby® technology for the development and the 
production of DNA vaccines free of antibiotic resistance gene.
Results
Since in our stabilization system, the antibiotic resistance gene is 
replaced by a gene encoding an antidote protein, our first objec-
tive was to evaluate the possible toxicity of the plasmid (pStaby-
CMV-2) and particularly the putative toxicity of the CcdA 
antidote protein. To reach this goal, 293T human cells and 
B16F10 murine cells were co-transfected with the pVAX2-Luc 
as reporter and either pStabyCMV-2 (Staby; encoding the ccdA 
gene under control of a prokaryotic promoter) or pcDNA3.3-
CcdA (CMV; encoding the ccdA gene under control of a CMV 
promoter which is highly active in eukaryotes) or pcDNA3.3-
LacZN (LacZ) or pCaspase3-wt (Caspasewt) or pCaspase3-
mut (Caspasemut) (Fig. 2A and 2B). These last four plasmids 
were used as controls and replaced pStabyCMV-2 (equal molar 
quantities). 293T and B16F10 cells were efficiently transfected 
by lipofectamine 2000 as demonstrated by luciferase expres-
sion. The expression of luciferase was lower when these cells were 
transfected with the pCaspase3-wt. This can be explained by the 
toxicity of the protein encoded by this plasmid, resulting in a 
marked decrease of the number of living cells. This result was 
confirmed by the death to live cell ratio estimated using the LDH 
(lactate dehydrogenase) and MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assays (Fig. 2C–F). Together, 
the results demonstrated that pStabyCMV-2 is not toxic for 
eukaryotic cells. It is important to note that pStabyCMV-2 car-
ries the ccdA sequence but it does not induce its expression in 
human or murine cells because there is no eukaryotic promoter 
that controls its expression. Interestingly, we also demonstrated 
that the pcDNA3.3-CcdA that encodes the CcdA antidote under 
control of a CMV promoter did not provoke any toxicity. In 
order to evaluate the level of ccdA mRNA in the transfected cells, 
qPCR experiments were performed. RNA was isolated from cells 
(293-T and B16F10) which were transfected with pcDNA3.3-
CcdA, pStabyCMV-2, pcDNA3.3-LacZN or pStabyCMV-
2-GOI (StabyGOI; pStabyCMV-2 plasmid containing a gene 
of a human transmembrane protein) and a qPCR analysis was 
performed. Values for ccdA were normalized to values for actin 
which is constitutively expressed in these cells. We observed a 
higher expression when the ccdA gene is under the CMV pro-
moter (Fig. 2G–H). If this value was designated as 100%, the 
level of ccdA mRNA when the ccdA gene is under a prokaryotic 
promoter was lower than 1% in human 293T cells and was lower 
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mouse to induce complete immune protection as compared with 
previous studies that did not employ electroporation and used as 
much as 100 μg plasmid per mouse.27,28 One study that reported 
the use of gene gun for the delivery of a DNA vaccine used even 
lower amount of plasmid (3 μg), but even though it was able 
to induce neutralizing antibodies the titers were low (reciprocal 
dilution of sera containing neutralizing antibodies was 30 after 
2 immunizations, while in our system we observed that a mini-
mum dilution of 120 was needed to induce protection) and no 
protection was reported.30 A recent study in pigs confirmed that 
electroporation can improve the performance of DNA vaccine 
coding for glycoprotein B of SuHV-1.31
The present study demonstrated that electrotransfer of a 
Staby plasmid encoding SuHV-1 gD gene is effective in induc-
ing a humoral immune response (as revealed by indirect immu-
nofluorescent assay (MFI) and neutralization assay) and more 
importantly in conferring an immune protection against a lethal 
challenge.
Materials and Methods
pStabyCMV-2 (2,421 bp) contains the ccdA antidote gene under 
the control of a weak constitutive prokaryotic promoter while 
pcDNA3.3-CcdA (5,617 bp) encodes the ccdA gene under the 
control of the CMV promoter.12 pcDNA3.3-LacZN (8,467 bp) 
encodes β-galactosidase and was used as a control for the trans-
fection lethality. Two plasmids (6,808 bp each) encoding the cas-
pase-3 wt (highly apoptotic) or mutated (with a less pronounced 
effect) were used as positive controls of toxicity. These plasmids 
encoding caspases were a generous gift from Dr Kris Huygen.32 
Discussion
The last ten years, DNA vaccination has been a growing field 
of research. As explained above, the interest to DNA vaccine is 
linked to all its advantages over conventional vaccines: the stabil-
ity of the DNA, the ease of development and production, the 
ability to induce a wider range of immune response types and the 
assurance to produce the antigen with post-translational modi-
fications. However, conventional DNA vaccines represent a risk 
for public health as this kind of vaccine contains an antibiotic 
resistance gene. To avoid the spread of resistance genes in envi-
ronment we propose to exchange these genes by the Staby® tech-
nology. This technology is based on the ccd system (ccdA/ccdB) 
naturally present in bacteria. The ccdB gene is inserted in the 
bacterial chromosome and codes for a poison while the ccdA gene 
is present on the plasmid and codes for the antidote. This system 
gives a very strong stability to the plasmid during cell growth and 
plasmid production.
We report in this study the development of a new plasmid vec-
tor designed for use in vaccination. This vector, pStabyCMV-2 
contains the cytomegalovirus immediate early promoter (CMV) 
to produce the antigen with a high expression rate in eukaryotic 
cells and the antidote gene ccdA to produce the DNA vaccine 
plasmid without the use of antibiotics. As the pStabyCMV-2 will 
be the final product injected to the patient, it was obvious to test 
and to prove the safety of the CcdA protein in eukaryotic cells. 
We effectively showed that the stabilization technology and par-
ticularly the ccdA antidote gene present on the plasmid are safe 
for eukaryotic cells even when it is artificially overexpressed.
The Staby® technology has been proved compatible with any 
culture medium or process used for production. Here, we demon-
strated that high yield of industrial plasmid DNA production is 
achievable using this plasmid stabilization technology.
As the CcdA protein is not toxic for eukaryotic cells and that 
the industrial production is feasible, we designed an antibiotic-
free DNA vaccine against Aujeszky’s disease. Currently, vaccina-
tion against Aujeszky’s disease is performed with different types 
of vaccines – inactivated, attenuated, subunits and recombinant. 
From all the glycoproteins of SuHV-1, gD was selected as candi-
date antigen since it has been shown to play an essential role in 
viral entry and to represent a major target for neutralizing anti-
bodies, protecting mice and swine from Aujeszky’s disease.23-26
This study confirms that mice can be effectively protected 
against SuHV-1 infection by electrotransfer of a plasmid encod-
ing gD as the single antigen, in contrast to a combination of 
plasmids coding for the three major SuHV-1 glycoproteins.27-29 
Moreover the immunization program used in the present study 
relied on a strategy to reduce the quantity of injected DNA by 
using electroporation as a delivery method. We used 20 μg/
Figure 3. Flowchart of the experiments performed to assess the safety 
and the efficacy of pstabycMV-2-gD as a DNa candidate vaccine against 
aujeszky’s disease. Mice (n = 10) were immunised by DNa electrotrans-
fer of pstabycMV-2-gD or pstabycMV-2 (used as negative control). at 
the indicated times, blood samples were collected and analyzed for 
detection of anti-gD antibodies (see Fig. 4A and B). seventy days after 
the first plasmid electrotransfer, mice were challenged by injection with 
the Phylaxia strain of suhV-1 (see Fig. 4C).
Figure 2 (See opposite page). ccda in vitro toxicity in 293T cells (A, C, E and G) and B16F10 cells (B, D, F and H). Both cells were cotransfected with 
the pVaX2-Luc as reporter and either pstabycMV-2 (staby) or pstabycMV-2-GOI (stabyGOI) or pcDNa3.3-ccda (cMV) or pcDNa3.3-LacZN (LacZ) or 
pcaspase3-wt (caspasewt) or pcaspase3-mut (caspasemut). (A, B) cells containing the pcaspase3-wt show a lower expression of the Luc reporter 
gene suggesting toxicity. (C, D) LDh and MTT assays did not revealed any toxicity of the pstabycMV-2 or pcDNa3.3-ccda. (E, F) The death to live cell 
ratio, obtained from results of the LDh and MTT tests showed significant toxicity for the wild-type caspase-3 encoding plasmid only. (G, H) qPcRs 
show the innocuousness overexpression of the ccda gene. statistical analysis: One-way aNOVa with Tukey post-test. **p value < 0.01, ***p value < 
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96-well plates 24 h before transfection. Cells were cotransfected 
with 0.02 pmol of pVAX2-Luc and 0.02 pmol of pcDNA3.3-
CcdA, pStabyCMV-2, pcDNA3.3-LacZN, pCaspase3-wt or 
pCaspase3-mut. A pVAX2-empty plasmid was added to reach 
the same total plasmid quantities (i.e., 0.2 μg) for each condi-
tion. Cotransfection of the three plasmids was performed using 
lipofectamine 2000 following the manufacturer’s recommen-
dations (Invitrogen). The luciferase expression was first mea-
sured using OneGlo (Promega). Then, in parallel, MTT and 
LDH cytotoxicity assays were performed 72 h after transfec-
tion. MTT measures the mitochondrial succinate deshydroge-
nase activity and provides an evaluation of cell viability.34 LDH 
measures lactate dehydrogenase which is released by damaged 
cells and provides therefore an evaluation of cell mortality.35 For 
qPCR analysis of ccdA expression, 293T and B16F10 (80,000 
and 40,000 cells per well, respectively) were plated using 12-well 
plates and transfected as described above. Total RNA was iso-
lated and purified using trizol and PureLinkRNA mini kit 
(Ambion) 72 h after transfection. Total ARN was treated by 
TURBO DNase (Ambio) and used for reverse transcription 
with Maxima Reverse Transcriptase (Thermo Scientific) and 
oligo (dT) primer. A quantitative PCR (qPCR) assay was per-
formed using the LightCycler 480 instruments (Roche) with 
LightCycler 480 Probes Master. For ccdA amplification, we 
used primers 5'-GTAAGCACAA CCATGCAGAA TGA-3', 
5'-CCTTCCTGAT TTTCCGCTTT C-3' and Taq Man probe 
5'-CCCGTCGTCT GCGTGCCG-3'. Values for ccdA were 
normalized to values for actin. We used Pre-developed TaqMan 
Assay Reagents control Kit (Applied Biosystems) for human 
(293T cells) or mouse (B16F10 cells) actin amplification. Values 
obtained from the pcDNA3.3-CcdA samples were designated as 
100%. Experiments were performed in triplicate.
The industrial fermentation process was realized with E. coli 
CYS21 strain (containing the ccdB gene in its chromosome; 
Delphi Genetics) transformed with pStabyCMV-2-GOI.
SuHV-1 gD ORF (Gene bank sequence ID 2952521) was 
cloned into pStabyCMV-2 resulting in pStabyCMV-2-gD DNA. 
Bovine mammary epithelial cells (MAC-T) were used for trans-
fection experiments. SuHV-1 Phylaxia strain was propagated and 
titrated in Swine testis cells (ST).
DNA immunization was performed as follows. Six weeks old 
female Balb/c mice were injected with alum (10 mg/ml, 50 μl/
mouse; Thermo Scientific) in both tibialis cranialis the day before 
DNA immunization. The following day, 20 μg of DNA plasmid 
diluted in 50 μl of PBS was injected into tibialis cranialis (10 μg 
per leg). Then, we placed the leg between plate electrodes and we 
delivered 8 square-wave electric pulses (200 V/cm, 20 ms, 2 Hz). 
Conductive gel was used to ensure electrical contact with the skin 
(EKO ultrasound transmission gel). The pulses were delivered 
by a Cliniporator system (IGEA) using 4 mm plate electrodes 
(IGEA) as previously described.36 All mice were immunized three 
times at an interval of three weeks. Mouse blood was collected 
from the caudal vein one week after each immunization. Blood 
samples were incubated overnight at 4°C, centrifuged for 10 min 
at 1,000 g and the supernatants were transferred into sterile tubes 
and stored at −20°C until use.
pVAX2-Luc (4,626 bp) encoding luciferase under the control of 
the CMV promoter was used to check the efficacy of each trans-
fection. The pVAX2-Luc and the pVAX2-empty plasmids (2,933 
bp) were kindly provided by Dr Pascal Bigey (Paris, France).33 
Plasmids were prepared using Qiagen Endofree Plasmid Maxi or 
Giga Kit according to the manufacturer’s protocol. All plasmid 
dilutions were done in PBS and stored at −20°C before use.
Two types of eukaryotic cells were used: 293T human embry-
onic kidney cells (8,000 cells per well) and B16F10 murine 
melanoma cells (4,000 cells per well). Cells were plated in 
Figure 4. evaluation of the immune response induced by pstabycMV-
2-gD in mice. (A) specific antibodies raised against suhV-1 gD were 
detected by indirect immunofluorescent staining of Mac-T cells 
transfected with pstabycMV-2-gD using sample sera as primary 
antibodies. The MFI of labeled cells was measured by flow cytometry. 
(B) Neutralizing antibodies were quantified by complement indepen-
dent neutralization assay. symbol *** indicates statistical differences 
(p ≤ 0.01; paired student’s t test; Graph Pad software) observed for a 
specific time point between pstabycMV-2-gD and pstabycMV-2 groups 
(symbol above rectangle), or between different time points within the 
group of animals vaccinated with the pstabycMV-2-gD. (C) Immunized 
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In order to test the protection induced by immunization, the 
mice were challenged by intramuscular injection into the quadri-
ceps of 2,800 pfu of SuHV-1 Phylaxia strains. Challenged mice 
were examined twice daily. According to bioethical rules, mice 
that expressed pruritus for more than 12 h and/or performed 
auto mutilation were euthanized. The experiments performed in 
the present study were approved by the bioethical comity of the 
Université de Liège (Ethical protocol number 1194).
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Anti-gD antibodies were detected by indirect immunofluores-
cent staining of MAC-T cells transiently expressing gD. MAC-T 
cells were transfected with 2 μg of plasmid (pStabyCMV-2-gD 
and pStabyCMV-2) in the presence of polyethylenimine accord-
ing to the manufacturer’s instructions (Polysciences). Twenty-
four hours post transfection staining with mouse sera at a 1:150 
dilution was performed, followed by goat anti-mouse Alexa 488 
secondary antibody. The mean fluorescent channel of positive 
cells was detected by flow cytometry.
Anti-gD neutralizing antibodies were analyzed by a comple-
ment independent neutralization assay. Mice sera were inac-
tivated for 30 min at 56°C and then serially diluted 2-fold in 
96-well plates, mixed with 7 plaque-forming units (pfu) of 
SuHV-1 Phylaxia strain and incubated for 2 h at 37°C. After 
incubation the sera-virus mix was added to 1 x 104 ST cells/well 
in 96-well plates and incubated for 4 d at 37°C (8 replicates). 
After four days, cell monolayers were examined for cytopathic 
effect. Neutralization titers were calculated as the reciprocal 
highest serum dilution preventing cytopathic effect.
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